News
BMY
48.82
+1.08%
0.52
Sellas Life Sciences Group: A Lottery Ticket With An Estimated 9x Payout
SELLAS Life Sciences Group, Inc. Is a late-stage biotech company with a leading drug candidate, GPS. GPS is an immunotherapy drug targeting the Wilms Tumor 1 antigen, which is overexpressed in AML patients. The AML market size is estimated to be $3.1 billion. The GPS phase 3 clinical trial interim report is scheduled to be read out in April. GPS has a 44% probability of success and a potential 9x return.
Seeking Alpha · 51m ago
LIVE MARKETS-Investors get ready for key week in earnings
Next week is expected to be one of the busiest weeks of the U.S. Earnings season. First-quarter S&P 500 earnings are expected to have risen just 2.9% from the year-ago quarter. Investors get ready for key week in earnings.
Reuters · 56m ago
Validea Detailed Fundamental Analysis - BMY
NASDAQ · 5h ago
FDA Mandates "Boxed Warning" For Bristol Myers, Johnson & Johnson CAR-T-Based Blood Cancer Therapies
The FDA said on Thursday it will require boxed warnings for all CAR-T cancer therapies. The blood cancer treatments may pose a risk of secondary cancers, the agency said. In November, the FDA announced it was investigating reports of patients developing T-cell malignancies. The agency asked drugmakers to add a boxed warning to the products in January.
Benzinga · 5h ago
Got $500? 3 Healthcare Stocks to Buy and Hold Forever
Make the most of a modest investment by putting it into Intuitive Surgical, Bristol Myers Squibb, and Novo Nordisk. The healthcare industry can be a good place to invest for the long term. Three companies that trade at less than $500 each look like attractive long-term buys. Robotic-assisted surgery is the future of healthcare.
The Motley Fool · 6h ago
FDA requires labeling changes to CAR-T cell therapies to reflect cancer risk
FDA requires labeling changes to CAR-T cell therapies to reflect cancer risk. New class of cancer treatments will require updates to their safety information to indicate a severe risk of secondary malignancies. The issue relates to a new class of CAR T cell therapies, the FDA says.
Seeking Alpha · 8h ago
US FDA mandates label updates on CAR-T cancer therapies
US FDA mandates label updates on CAR-T cancer therapies that use CAR-t technology. The agency said the changes will highlight the serious risk of T-cell blood cancer in patients who use these therapies. In January, the FDA asked drugmakers to add a boxed warning to their therapies.
Reuters · 20h ago
Bristol-Myers Squibb Price Target Raised to $52.00/Share From $51.00 by Wells Fargo
Dow Jones · 1d ago
Bristol-Myers Squibb Is Maintained at Equal-Weight by Wells Fargo
Dow Jones · 1d ago
Wells Fargo Maintains Equal-Weight on Bristol-Myers Squibb, Raises Price Target to $52
Benzinga · 1d ago
Interesting BMY Put And Call Options For December 20th
NASDAQ · 1d ago
Johnson & Johnson: Buy This Bargain Before It's Gone
Johnson & Johnson released financial results for the first three months of 2024. Tecvayli sales were $133 million in the first quarter of 2024, up 111% year over year. I am upgrading Johnson & Johnson's rating from 'Buy' to 'Strong Buy' The company's share price has declined by 4% since the publication of my last article in early 2024. Key contributors to improving the company's financial position are next-generation medications.
Seeking Alpha · 1d ago
AbbVie buyout Cerevel posts late-stage win for Parkinson’s disease drug
AbbVie's buyout target Cerevel Therapeutics posts late-stage win for Parkinson’s disease drug. Cerevel's oral, once-daily Parkinson's disease candidate, tavapadon, reached its main goals in a pivotal Phase 3 trial as a combination therapy. The company agreed to acquire Cerevel in December for $8.7B.
Seeking Alpha · 1d ago
BRISTOL-MYERS SQUIBB COMPANY <BMY.N>: WELLS FARGO RAISES TARGET PRICE TO $52 FROM $51
Reuters · 1d ago
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Accolade (ACCD), Ultragenyx Pharmaceutical (RARE) and Bristol-Myers Squibb (BMY)
TipRanks · 1d ago
BRISTOL-MYERS SQUIBB CO <BMY.N>: WELLS FARGO RAISES TARGET PRICE TO $52 FROM $51
Reuters · 1d ago
U.S. RESEARCH ROUNDUP- Builders Firstsource, Eli Lilly, Northern Trust
Wall Street analysts revise their ratings and price targets on several U.S.-listed companies. Builders Firstsource, Eli Lilly, Northern Trust and Abbott Laboratories are among those. Alphabet Inc raises its target price to $165 from $160. TenX Genomics Inc, a maker of DNA sequencing equipment, is downgraded to hold from sell.
Reuters · 1d ago
Bristol-Myers Squibb: Market Pessimism Won't Last Forever
Bristol-Myers Squibb Company stock continues to struggle at a four-year low. Revlimid's revenue decline and increased competition from generics pose significant challenges for the company. The company needs to convince investors that its recent M&A can improve performance significantly. Selling pressure on Bristol- myers has abated, providing solid opportunities for long-term investors.
Seeking Alpha · 2d ago
2seventy bio (TSVT) Rises More Than 50% in 3 Months: Here's Why
NASDAQ · 2d ago
2 High-Yield Dividend Stocks to Buy and Hold for 10 Years
Bristol Myers Squibb and Novartis are income-seeking stocks with a high dividend yield of about 5%. The drugmakers have been suffering from slow top-line growth in recent years. Both companies have a strong pipeline of new drugs and are developing new products. Bristol Myers has increased its dividend payouts by 46% in the past five years.
The Motley Fool · 2d ago
More
Webull provides a variety of real-time BMY stock news. You can receive the latest news about Bristol-Myers Squibb Co through multiple platforms. This information may help you make smarter investment decisions.
About BMY
Bristol-Myers Squibb Company is a biopharmaceutical company engaged in the discovery, development and delivering advanced medicines that help patients prevail over serious diseases. It offers products for various therapeutic classes, which includes oncology, hematology, immunology, cardiovascular and neuroscience. Its pharmaceutical products include chemically synthesized or small molecule drugs, products produced from biological processes, called biologics and chimeric antigen receptor (CAR-T) cell therapies. Small molecule drugs are typically administered orally in the form of a tablet or capsule, although other drug delivery mechanisms are used as well. Biologics are administered to patients through injections or by intravenous infusion. Its in-line products include Eliquis, Opdivo, Orencia, Pomalyst/Imnovid, Yervoy, Sprycel, Reblozyl, Opdualag, Abecma, Zeposia, and others. The Company's product pipeline includes Krazati, MRTX1719, RYZ101, KarXT, ORM-6151, and Repotrectinib.